Zacks Investment Research·6 days ago
NovoCure's Cancer Treatment Device Option Pax Gets European ApprovalNVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment after strong late-stage trial results.
NovoCure Limited(NVCR)Earnings, Financials & Key Ratios
NVCR•NASDAQ
$17.72
Price updated Jul 7, 2026
AboutNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Show more
- Revenue$655M+8.3%
- EBITDA-$137M+14.2%
- Net Income-$136M+19.2%
- EPS (Diluted)-1.22+21.8%
- Gross Margin74.54%-3.6%
- EBITDA Margin-20.84%+20.8%
- Operating Margin-23.47%+16.7%
- Net Margin-20.79%+25.4%
- ROE-38.89%+16.7%
NVCR Price & Volume
NovoCure Limited (NVCR) stock price & volume — 10-year historical chart
Loading chart...
Decelerating Revenue Growth Masks Persistent Operational Losses
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Dependency
Key Thesis Takeaways
- NovoCure faces a challenging outlook as revenue growth has decelerated to 12.3% in 2026Q1, signaling potential market saturation for its TTFields therapy.
- The company's reliance on high SG&A spending, which reached $144.2 million in the most recent quarter, continues to outpace revenue gains and prevents the achievement of operating leverage.
- Investors should remain cautious given the significant cash burn and the erosion of total equity to $330.7 million, which may necessitate further dilutive financing to support ongoing clinical development.
Verdict Logic
the company's persistent negative operating margin of -38.7% and the rapid depletion of cash reserves to $97.3 million suggest significant long-term financial sustainability risks.
NVCR Growth Metrics
NovoCure Limited (NVCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years34.8%
5 Years5.8%
3 Years6.81%
TTM8.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.32%
Return on Capital
10 Years-15.96%
5 Years-17.81%
3 Years-25.22%
Last Year-28.87%
NVCR Recent Earnings
NovoCure Limited (NVCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.62-21.0%
$0.51
Rev
$174M+3.7%
$168M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.22+46.3%
$0.41
Rev
$174M-0.0%
$174M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.33+21.4%
$0.42
Rev
$167M-4.1%
$174M
Q3 2025
Jul 24, 2025Metric
Actual
Est
EPS
$0.36+7.7%
$0.39
Rev
$159M-0.0%
$159M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.62vs $0.51-21.0% | $174Mvs $168M+3.7% |
| Q1 2026 | Feb 26, 2026 | $0.22vs $0.41+46.3% | $174Mvs $174M-0.0% |
| Q4 2025 | Oct 30, 2025 | $0.33vs $0.42+21.4% | $167Mvs $174M-4.1% |
| Q3 2025 | Jul 24, 2025 | $0.36vs $0.39+7.7% | $159Mvs $159M-0.0% |
Based on last 12 quarters of dataView full earnings history →
Latest NVCR News
Recent stock market news and headlines for NovoCure Limited (NVCR)
Business Wire·6 days ago
Novocure to Report Second Quarter 2026 Financial ResultsBAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company's financial results for the three-month period that ended June 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access.
Business Wire·Jun 30, 2026
Novocure's Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic CancerBAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. “Pancreatic cancer is often diagnosed in late stages when tumors are more difficult to treat. As a result, treatment options have limited effect and survival.
Fool - Investing News·Jun 24, 2026
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
Fool - Investing News·Jun 22, 2026
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Peers Comparison
Key metrics vs top competitors for NovoCure Limited (NVCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.72 | $2.02B | -14.52 | 8.28% | -20.79% | -38.89% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $570.25 | $45.29B | 43.60 | 10.42% | 24.63% | 70.87% | — |
Compare NVCR vs Peers
NovoCure Limited (NVCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NVCR SEC Filings & Documents
NovoCure Limited (NVCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 26, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when NVCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NVCR Frequently Asked Questions
NovoCure Limited (NVCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is NovoCure Limited's revenue?
NovoCure Limited (NVCR) reported $674.4M in revenue for fiscal year 2025. This represents a 6410% increase from $10.4M in 2013.
How fast is NovoCure Limited growing?
NovoCure Limited (NVCR) grew revenue by 8.3% over the past year. This is steady growth.
Is NVCR profitable?
NovoCure Limited (NVCR) reported a net loss of $173.0M for fiscal year 2025.
Dividend & Returns
What is NVCR's return on equity?
NovoCure Limited (NVCR) has a return on equity (ROE) of -38.9%. Negative ROE indicates the company is unprofitable.
What is NovoCure Limited's free cash flow?
NovoCure Limited (NVCR) had negative free cash flow of $48.1M in fiscal year 2025, likely due to heavy capital investments.